Noile-Immune Biotech Inc.

Tokyo Stock Exchange 4893.T

Noile-Immune Biotech Inc. Gross Profit Margin for the year ending December 31, 2023: 99.29%

Noile-Immune Biotech Inc. Gross Profit Margin is 99.29% for the year ending December 31, 2023, a 0.42% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Noile-Immune Biotech Inc. Gross Profit Margin for the year ending December 31, 2022 was 98.87%, a 27.96% change year over year.
  • Noile-Immune Biotech Inc. Gross Profit Margin for the year ending December 31, 2021 was 77.27%, a -20.30% change year over year.
  • Noile-Immune Biotech Inc. Gross Profit Margin for the year ending December 31, 2020 was 96.95%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Tokyo Stock Exchange: 4893.T

Noile-Immune Biotech Inc.

CEO Mr. Koji Tamada M.D., Ph.D.
IPO Date June 28, 2023
Location Japan
Headquarters 2-12-10
Employees 28
Sector Health Care
Industries
Biotechnology
Description

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email